Physician profile
Madhu Gupta
NPI 1265628473
$3,242.07
in general payments reported to CMS, 2019-2025
26 companies · $732 in 2025
The $732 reported for 2025 was more than what 80% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $122 · 2020: $216 · 2021: $233 · 2022: $409 · 2023: $469 · 2024: $1,060 · 2025: $732.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,244 · Education: $17.44.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,243.71 |
| Education | $17.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $708.91 | 2019-2025 | Evenity, Prolia |
| Astrazeneca Pharmaceuticals LP | $531.01 | 2023-2025 | Breztri, Farxiga, Airsupra |
| Bayer Healthcare Pharmaceuticals INC. | $334.36 | 2022-2025 | |
| Novo Nordisk INC | $324.31 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Pfizer INC. | $319.15 | 2019-2025 | |
| Lilly USA, LLC | $163.59 | 2024-2025 | Zepbound, Mounjaro |
| Glaxosmithkline, LLC. | $152.18 | 2024-2025 | Shingrix, Arexvy |
| Merck Sharp & Dohme LLC | $129.42 | 2022-2025 | Capvaxive, Gardasil 9, Gardasil |
| Exact Sciences Corporation | $85.17 | 2025 | Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $69.44 | 2021-2024 | Xifaxan |
| Abbvie INC. | $59.59 | 2023-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $48.46 | 2022 | |
| Sunovion Pharmaceuticals INC. | $35.97 | 2022 | |
| Agios Pharmaceuticals, INC. | $35.42 | 2024 | Pyrukynd |
| Otsuka America Pharmaceutical, INC. | $33.32 | 2023 | Nuedexta |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almatica Pharma LLC | $29.58 | 2024 | Loreev Xr |
| Janssen Pharmaceuticals, INC | $26.96 | 2025 | Spravato |
| Corium, LLC | $24.96 | 2022 | |
| Insmed, INC. | $22.48 | 2022 | |
| Edwards Lifesciences Corporation | $19.53 | 2024 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Idorsia Pharmaceuticals US INC | $19.07 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.10 | 2020 | |
| Amarin Pharma, INC. | $17.75 | 2019 | |
| Currax Pharmaceuticals LLC | $16.67 | 2024 | Contrave |
| Genentech USA, INC. | $15.47 | 2019 | |
| Dynavax Technologies Corporation | $1.20 | 2023 | Heplisav-B |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Madhu Gupta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.